Koronaios: Russian Sputnik vaccine ‘92% effective’



Two days after announcing promising but preliminary results for the Pfizer / BioNtech candidate vaccine against Covid-19 coronavirus, Russian authorities announced on Wednesday that the Sputnik V vaccine prevents 92% of infections. In the West, however, the claim has been met with some skepticism. To date, little is known about the protocol of the clinical trial of the Russian vaccine and confirmation of the claim is not possible, independent experts told Reuters. In Moscow, however, the enthusiasm is big: the Russian Direct Investment Fund, which announced the success of the vaccine, launched a website and Twitter account for Sputnik V, where it will offer “the latest news about the vaccine” as well as “personal testimonies and thoughts” of people who In Russia, Sputnik V vaccinations have begun before clinical trials are completed. No European country has ordered Russian vaccines so far, but Turkey is expected to become a major customer of Russia and may take over production. “Sputnik data is further good news for Covid-19 vaccine development,” Ian told Reuters Jones, Professor of Virology at the University of Reading in the UK. [η ανακοίνωση] “The Russian vaccine does not seem to be as effective as the recent Pfizer data,” he said. “However, the Russian announcement did not cause the spectacular rise in markets seen after the Pfizer announcement.” The lack of reactions from the markets highlights “There is an element of suspicion about the findings, and it is unlikely that there will be a high level of acceptance among Western countries,” said Joshua Mahoney, an analyst at IG. for Russian vaccines because most people do not trust Moscow in such matters. Concerns about their effectiveness and safety have not been allayed. Simply put, no one believes Putin. “Follow it on Google News and be the first to know all the news See all the latest news from Greece and the world,



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *